Market Research Logo

Hospital-Treated Sepsis Part 2: Treatment

Hospital-Treated Sepsis Part 2: Treatment

In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 272 million encounters for 60 million patients in 600+ hospitals across the US, Boston Strategic Partners (BSP) estimates 30% of all hospital discharges involve treatment of infectious organisms. Sepsis is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of sepsis patient characteristics, medication management, costs, and laboratory testing.

Gram-positive bacteria are the likely causative agents of most sepsis infections. Physicians treat the vast majority of these infections with vancomycin, piperacillin-tazobactam, levofloxacin, and ceftriaxone. After confirmatory diagnosis, over half of sepsis patients undergo a change in antibiotic therapy.

Hospital-Treated Sepsis Part 2: Treatment is part two of a two-part series on hospital-treated sepsis. This report provides quantitative, objective data focused on the treatment of sepsis requiring hospitalization captured by hospitals contributing to Cerner Health Facts. This data provides real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antimicrobial stewardship.

Focused on sepsis requiring hospitalization, detailed analysis of over 680K hospital discharges from 2009 to 2015 (including projections through 2019)
Epidemiology of infection in the US, including demographic information, growth, overall patient encounter attributes, and most common causative agents
An overview of patients with sepsis in the US, including region, gender, and age breakdown, payer type, infection type, associated patient comorbidities, and antibiotic usage
Analysis of mortality, total costs, and admission data and how they correlate with the following:

Age of patient
APACHE II score
Care setting
Antibiotic usage

Examination of frequently ordered lab tests and cultures with data on turnaround time (TAT) and results
Assessment of confirmatory diagnostic results, empiric therapy, and how results impact empiric therapy
Treatment duration of frequently used antibiotics


1 Patient Flow
2 Executive Summary
3 Incidence and Impact of Disease
3.1 Incidence
3.2 Length of Stay
3.3 Total Cost
4 Patient Demographics
4.1 Age
4.2 Insurance type
4.3 Gender
4.4 Region
4.5 Mortality
4.6 Comorbid Conditions
5 Patient Flow through the Hospital
5.1 Admission Site
5.2 Lab Testing
5.3 Lab TAT
5.4 Results
5.5 Etiology
5.6 Empiric Therapy
5.7 Change in treatment
6 Drug Share for Key Therapeutics
6.1 Most Common
6.2 LOS
6.3 APACHE Score
6.4 Treatment Duration
6.5 Product Dashboards
6.5.1 Market Share
6.5.2 Demographics
6.5.3 Hospitalization
7 Outcomes of Treatment
7.1 Antibiotic Usage
7.2 Mortality
7.3 Cost per Patient
8 Database Overview
9 Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report